Skip to main content

Prescription medicine

Azilsartan and chlorthalidone Brand names: Edarbyclor

Azilsartan and chlorthalidone (Edarbyclor) is a prescription medicine with an FDA approval on record since 2011. No generic is listed; pharmacies paid $8.49 per Edarbyclor 40-12.5 mg tablet in the October 7, 2026 NADAC survey.

  • No generic listed
  • Boxed warning

Check it at the source: the azilsartan and chlorthalidone FDA label on DailyMed (effective July 1, 2022, Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)); the NDA 202331 record on Drugs@FDA; every azilsartan and chlorthalidone label on DailyMed.

Highlights of the record

FDA label of July 1, 2022; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026

Boxed warning

FETAL TOXICITY.

When pregnancy is detected, discontinue Edarbyclor as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue EDARBYCLOR as soon as possible ( 5.1 , 8.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus

Used for

From the label: indications and usage

Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure.

Forms and strengths

  • 40 mg / 25 mg
  • 40 mg / 12.5 mg

Tablet.

On the market

Earliest approval on file
December 20, 2011 Edarbyclor, Azurity; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals
1 first January 21, 2025; 1 with a marketed status in Drugs@FDA
Labelers listed (NDC)
1 of which 0 under generic applications, 1 under brand applications, repackagers included
Last listed patent
July 1, 2031 Edarbyclor tablets; not a generic launch date

Supply and safety

Pharmacy cost (NADAC)
$8.49 per tablet Edarbyclor 40-12.5 mg tablet
Shortage (FDA)
No current entry
Recalls by its makers (FDA)
2 since 2021 0 Class I among all firms' recalls; latest March 15, 2021
FAERS reports
1,253 through July 30, 2026

What is azilsartan and chlorthalidone used for?

From the label: indications and usage

Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. […]

Conditions named in the indications of azilsartan and chlorthalidone's FDA labels, with every medicine labeled for each:

FDA pharmacologic class: Angiotensin 2 Receptor Blocker and Thiazide-like Diuretic.

Source: FDA drug label (Edarbyclor), Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals), effective July 1, 2022 (SPL set e60f795b-fce3-4361-aa03-f143451689d1), via openFDA; the full label on DailyMed

What does the patient leaflet for azilsartan and chlorthalidone say first?

The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.

From the patient leaflet: What is the most important information I should know about Edarbyclor?

Edarbyclor can cause harm or death to your unborn baby. Talk to your doctor about other ways to lower your blood pressure if you plan to become pregnant. If you become pregnant while taking Edarbyclor, tell your doctor right away. Your doctor may switch you to a different medicine to treat your high blood pressure. What Is Edarbyclor? Edarbyclor is a prescription medicine that contains azilsartan medoxomil, an angiotensin receptor blocker (ARB) and chlorthalidone, a water pill (diuretic). Edarbyclor is used to treat high blood pressure (hypertension): when one medicine to lower your high blood pressure is not enough as the first medicine to lower your high blood pressure if your doctor decides you are likely to need more than one medicine. It is not known if Edarbyclor is safe and effective in children under 18 years of age. Who should not take Edarbyclor? Do not take Edarbyclor if you: make less urine because of kidney problems

From the patient leaflet: How should I store Edarbyclor?

Store Edarbyclor at room temperature between 68°F to 77°F (20°C to 25°C). Store Edarbyclor in the original container that you received from your pharmacist or doctor. Do not put Edarbyclor into a different container. Keep the container closed tightly, and keep Edarbyclor out of the light. Keep Edarbyclor and all medicines out of the reach of children.

Source: FDA drug label (Edarbyclor), Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals), effective July 1, 2022 (SPL set e60f795b-fce3-4361-aa03-f143451689d1), via openFDA; the full label on DailyMed

Is there a generic for azilsartan and chlorthalidone (Edarbyclor)?

The FDA approved the first generic azilsartan and chlorthalidone on January 21, 2025. 1 generic application is approved; 1 of it carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.

The Orange Book lists 3 patents for Edarbyclor tablets, the last expiring on July 1, 2031. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

  • 2011 earliest approval on file
  • 2025 first generic approved
  • 2031 last listed patent
  • red ticks recalls

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What do pharmacies pay for azilsartan and chlorthalidone (Edarbyclor)?

In CMS's NADAC survey of October 7, 2026, pharmacies paid $8.49 per Edarbyclor 40-12.5 mg tablet, about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.

  • Edarbyclor 40-25 mg tablet (brand)
$8.50
$7.80
January 2024October 2026
NADAC per unit, October 7, 2026
Strength and formBrand or genericPharmacy cost30 tablets, or one pen or vial12-month change
Edarbyclor 40-12.5 mg tabletBrand$8.49 per tablet$254.83-0.1%
Edarbyclor 40-25 mg tabletBrand$8.49 per tablet$254.71+0.3%

Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price

Has azilsartan and chlorthalidone been recalled?

The FDA's Enforcement Report lists 2 recalls naming azilsartan and chlorthalidone since 2021: 0 Class I (the most serious), 2 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.

StartedClassCompanyReason
March 15, 2021Class IICardinal Health Inc.CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026

What does the azilsartan and chlorthalidone label say about other medicines?

The azilsartan and chlorthalidone label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Medicine namedSectionWhat the label says
Aliskirendrug interactionsBlockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
Lithiumdrug interactionsDRUG INTERACTIONS Renal clearance of lithium is reduced by diuretics, such as chlorthalidone increasing the risk of lithium toxicity ( 7 ) NSAIDS increase risk of renal dysfunction and interfere with antihypertensive effect ( 7 ) Dual inhibition of the renin-angiotensin system:

Check azilsartan and chlorthalidone against other medicines

Source: FDA drug label (Edarbyclor), Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals), effective July 1, 2022 (SPL set e60f795b-fce3-4361-aa03-f143451689d1), via openFDA; the full label on DailyMed

What do FAERS reports show for azilsartan and chlorthalidone?

The FDA Adverse Event Reporting System holds 1,253 reports that list azilsartan and chlorthalidone among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 39 are coded as a death and 219 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

Reports received each year

The most reported reactions

  • Dizziness (named in the label)107
  • Fatigue (named in the label)78
  • Blood Pressure Increased72
  • Drug Ineffective (a use or a product term, not a reaction)67
  • Diarrhoea (named in the label)62
  • Nausea (named in the label)62
  • Hypotension (named in the label)58
  • Headache (named in the label)55

Side effects: the label's list and every FAERS reaction

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What else is labeled for the same conditions as azilsartan and chlorthalidone?

69 other medicines are given the same way (oral) and in the same FDA class as azilsartan and chlorthalidone or labeled mainly for the same use (high blood pressure), the same class first. High blood pressure lists all 88 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.

MedicineShared indicationGeneric labelers (oral)Pharmacy costShortage
LosartanHigh blood pressure44 labelers$0.0327 per tablet 50 mg tabletNo current entry
ValsartanHigh blood pressure34 labelers$0.0963 per tablet 40 mg tabletA presentation being discontinued
OlmesartanHigh blood pressure31 labelers$0.0805 per tablet 20 mg tabletNo current entry
Hydrochlorothiazide and losartanHigh blood pressure29 labelers$0.0762 per tablet 100-12.5 mg tabletNo current entry
Hydrochlorothiazide and valsartanHigh blood pressure18 labelers$0.101 per tablet 160-12.5 mg tabletNo current entry
IrbesartanHigh blood pressure23 labelers$0.107 per tablet 150 mg tabletNo current entry
TelmisartanHigh blood pressure28 labelers$0.106 per tablet 20 mg tabletNo current entry
Hydrochlorothiazide and olmesartanHigh blood pressure17 labelers$0.165 per tablet 20-12.5 mg tabletNo current entry

Every medicine labeled for the same conditions as azilsartan and chlorthalidone

Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)

What next?

Other ARBs
the pharmacologic class, with prices and generics
Azilsartan and chlorthalidone side effects
the label's list beside FAERS reports
Check an interaction
what two or more labels say about each other